Tag: UNIS

Blue Horseshoe Stocks: GTAT Recap & More

GT Advanced Technologies, Inc. GTAT

The unmatched winner of yesterday’s report definitely has to be GTAT. This gem came off of our extended watchlist, and had a breakout session. The impressive run began at a morning low of .88, and the stock continually pushed the envelope, reaching an afternoon high of 2.00.

The move came to an impressive intraday gain of 127% on 17X the three-month average volume. Cheers to all the folks who were able to carve a slice off of the pie!

The PPS did taper into the close, pulling back to 1.21, but is gapping up this morning, with GTAT thus far having traded as high as the 1.60’s in the premarket.

Recapping Yesterday’s Options Idea

Yesterday morning we raised a flag on the November $16 PBR Calls, and our bait wasn’t in the water long before we got a bite. PBR would briefly crack the $17-mark by early afternoon setting the stage for a solid chance.

Our contracts of interest traded in a range from 2.00 to as high as 2.70, making for a 35% intraday swing. With plenty of time before expiration, we could still see further action on the Nov. $16’s, so they’ll stay on our radar for the time being.

Extended Watchlist:
JNUG, SCOK, OXGN, UNIS, 

CNAT, GOGO, UNIS, CAMT & Extended Watchlist

Conatus Pharmaceuticals, Inc. CNAT

We caught CNAT on our scanner this morning, and is definitely a stock we’d like to keep an eye on today, following an FDA-related announcement regarding a drug that the company has under development receiving “Orphan Drug” status. FDA plays have provided us with countless opportunities in the past, especially when the news is untraded upon, so we’ll be interested to see how well CNAT fares today as a result.

SAN DIEGO, Dec. 2, 2013 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (CNAT), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Conatus’ drug candidate emricasan for the treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end-stage liver disease. The FDA’s Orphan Drug Designation program is intended to encourage the development of drugs and biologics that may provide benefit to patients suffering from rare diseases or conditions.

Conatus is developing emricasan, a first-in-class, orally active caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death (or apoptosis), for the treatment of patients with chronic liver disease and significant unmet medical need.

GOGO, Inc. GOGO

We have been hot on the trail of GOGO since our first mention on Monday Sept. 16th when it was trading as low as 14.79. We witnessed the stock’s 52-wk high a few weeks later on Nov. 14th (31.55), and then it consolidated to find support at 24.24.

Yesterday, GOGO re-established its 52-wk high at 31.65, and appears to want to gap up and continue its run today. This morning, the company has news out concerning the green light is has received to install its wifi satellite technology on Boeing 747 aircraft. and we’ve seen pre-market trades going off as high as 32.75. From our original alert price, that marks registers as a 121% gain. Heading into today’s session, we’d like to see the previous 52-wk high of 31.55 hold as support on any future pullbacks.

ITASCA, Ill., Dec. 2, 2013 /PRNewswire via COMTEX/ — Gogo (NASDAQ: GOGO), the world leader of in-flight connectivity and a pioneer in wireless in-flight digital entertainment solutions, passed a key milestone in launching its international connectivity service by receiving an STC to install its Ku-satellite technology on Boeing 747-400 aircraft.

Gogo will begin testing the new service immediately and plans to offer the service for customer usage by the first quarter of 2014. The technology will give travelers and crew access to the Internet. The service will also offer passengers Gogo Vision, Gogo’s wireless in-flight entertainment service.

Unilife Corp. UNIS

UNI hits our radar screens as another play with fresh news and a chart that is gapping up premarket. UNIS has a potentially lucrative arrangement in the works with European Pharma giant, Novartis.

YORK, Pa., Dec. 2, 2013 /PRNewswire/ — Unilife Corporation (“Unilife” or “Company”) (NASDAQ: UNIS, ASX: UNS) today announced an agreement with Novartis to supply clinical products from one of its platforms of injectable drug delivery systems for use with one of Novartis’ targeted early-stage pipeline drugs.

Under this agreement, Unilife will supply Novartis with a customized delivery device, consisting of syringe, needle, tubing, controller and pump, to enable administration of a novel investigational Novartis drug into a targeted organ in clinical trials. Unilife has granted Novartis an option for exclusivity under this agreement.


Camtek, Ltd. CAMT

Yesterday wasn’t the first time we’ve mentioned CAMT on our extended watchlist only to see the stock turn in an impressive performance; last Monday, we tagged CAMT as a possible runner, and subsequently witnessed a pop from 4.11-5.29 (+29%). In a repeat of that scenario, yesterday we saw the stock trade from a low of 4.20 on up to 5.75, for a possible gain of 37%

Cheers to anyone who was able to take advantage of those very timely alerts!

Extended Watchlist:
IACH, OMED, ETRM, FRO, DGLY, NAVB

Blue Horseshoe Stocks: FB & AAPL Options, INO, NOK, ZQK

Facebook FB OptionsThe FB 09/13 $41 Calls first appeared in our reports on September 4th, as we stated: “…if FB can breakout to $45 by next Friday, we could be looking at multi-bag gains from these contracts.” While we fell just shy of our target by .39 at Friday’s high of 44.61, the price action on those calls was still enough to provide us with those multi-bag gains with a whole trading week still remaining until expiration! So far, from their low following our 09/04 alert at 1.29, we saw a subsequent push to 3.80, good for a gain of 251% over a period of just a couple of days.

We’re going to remain bullish on these $41 Calls as we head into Friday’s expiration, as we think the chances are fair that FB as a whole remains on a general uptrend. It could lead us to move up on our strike price and contract duration as well. The 09/21 $45 Calls closed at .82 on Friday, and if Facebook does continue its upward momentum, those are likely to be the next contracts that will catch our interest.

Apple (AAPL) Options

There has been much speculation surrounding the possible focus of Apple’s big event tomorrow, which is widely believed to be an unveiling of the new iPhone 5S, although there have been no confirmations. Whenever a situation like this comes along, we always try to stay ready to advantage wherever possible. The public’s reaction to tomorrow’s event will determine our reaction in playing the Apple options chain. A successful reception and subsequent rise in PPS would obviously draw our attention to the Calls, while a disappointing result would force us to look at the Puts.

Inovio Pharmaceuticals, Inc. INO

We’ve been hot on the trail of INO since the beginning of July, when the stock was trading below a dollar (.7953 at its low). Within a month of that, by early August the stock had hit 3.03, which represented a move of 281%

We reminded everyone on August 23rd that we were observing higher highs and higher lows after the subsequent consolidation ( to a low of 1.60). Then on Friday, sent another reminder that INO was beginning to bounce back. We then saw a run back to 2.45, which marked a gain of 53%

This morning, the stock hit a high of 2.85 in pre-market trading, and trades are currently going off in the low 2.70’s.

Nokia Corp. NOK

Another stock that has done extremely well for us over an extended period is Nokia (NOK), especially recently, as its shares price ballooned on news that Microsoft had acquired its devices division as well as licensing rights to several of its patents. We’ve been following this stock for over a year now, and in that time we’ve seen a low of 1.91 run all the way up to recent highs in the high 5.50’s, a move of over 190%

Quiksilver, Inc. ZQKZQK appeared in Friday’s extended watchlist following release of an earnings report. After establishing a low at 5.99, the stock ran as high as  7.09, granting us the chance at an 18% intraday gain.

Extended Watchlist:
EXMT, BBRY, BLRX, UNIS, CLSN, MNTG